Table 2.

Factors decreasing glycated hemoglobin (HbA1c) in patients without drug change until month 12: analysis of factors causing changes in HbA1c levels (3–12 months)

Variables	Single regression analysis				Multiple regression analysis
	Regression coefficients	Lower limit of 95% CI	Upper limit of 95% CI	P value	Partial regression coefficient	Lower limit of 95% CI	Upper limit of 95% CI	P value
Sex (male)	0.041	− 0.080	0.162	0.501
Age	− 0.004	− 0.009	0.002	0.173	− 0.003	− 0.061	0.055	0.925
Smoking	0.226	0.079	0.373	0.003*	0.192	0.042	0.342	0.013*
Alcohol consumption	0.081	− 0.035	0.197	0.169	− 0.029	− 0.145	0.088	0.627
Duration of diabetes (year)	0.007	− 0.003	0.017	0.177	0.003	− 0.006	0.013	0.495
SBP (mmHg)	− 0.004	− 0.007	0.000	0.048*	− 0.004	− 0.008	0.000	0.060
BMI (kg/m2)	0.006	− 0.008	0.021	0.366
HbA1c (%)	0.001	− 0.067	0.069	0.982
Weight variations (3–12 months) (kg)	0.085	0.057	0.113	< 0.001*	0.081	0.054	0.109	< 0.001*
Antihypertensive drug use	− 0.070	− 0.188	0.047	0.238	− 0.084	− 0.203	0.036	0.169
Diet/exercise therapy alone	− 0.136	− 0.263	− 0.009	0.036*	− 0.076	− 0.214	0.063	0.283
Low-dose glimepiride	0.131	− 0.053	0.315	0.161	0.148	− 0.036	0.331	0.114
Medium-dose glimepiride	0.138	− 0.109	0.385	0.272
BG	− 0.054	− 0.223	0.115	0.532
TZD	− 0.041	− 0.288	0.206	0.746
α-GI	0.039	− 0.340	0.419	0.838
Multidrug therapy	0.072	− 0.055	0.199	0.265

BG biguanide, TZD thiazolidine, α-GI α-Glucosidase inhibitor, ANOVA analysis of variance, CI confidence interval

* P < 0.05 single or multiple regression analysis